Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study

Background Differences in access to care and treatment have been reported in Eastern Europe, a region with one of the fastest growing HIV epidemics, compared to the rest of Europe. This analysis aimed to establish whether there are regional differences in the mortality rate of HIV-positive individuals across Europe, and Argentina. Methods 13,310 individuals under follow-up were included in the analysis. Poisson regression investigated factors associated with the risk of death. Findings During 82,212 person years of follow-up (PYFU) 1,147 individuals died (mortality rate 14.0 per 1,000 PYFU (95% confidence interval [CI] 13.1–14.8). Significant differences between regions were seen in the rate of all-cause, AIDS and non-AIDS related mortality (global p<0.0001 for all three endpoints). Compared to South Europe, after adjusting for baseline demographics, laboratory measurements and treatment, a higher rate of AIDS related mortality was observed in East Europe (IRR 2.90, 95%CI 1.97–4.28, p<.0001), and a higher rate of non-AIDS related mortality in North Europe (IRR 1.51, 95%CI 1.24–1.82, p<.0001). The differences observed in North Europe decreased over calendar-time, in 2009–2011, the higher rate of non-AIDS related mortality was no longer significantly different to South Europe (IRR 1.07, 95%CI 0.66–1.75, p = 0.77). However, in 2009–2011, there remained a higher rate of AIDS-related mortality (IRR 2.41, 95%CI 1.11–5.25, p = 0.02) in East Europe compared to South Europe in adjusted analysis. Interpretations There are significant differences in the rate of all-cause mortality among HIV-positive individuals across different regions of Europe and Argentina. Individuals in Eastern Europe had an increased risk of mortality from AIDS related causes and individuals in North Europe had the highest rate of non-AIDS related mortality. These findings are important for understanding and reviewing HIV treatment strategies and policies across the European region.

[1]  J. Swinnen,et al.  Eastern Europe and Central Asia , 2019, Global Report on Trafficking in Persons.

[2]  O. Kirk,et al.  The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis , 2012, HIV medicine.

[3]  J. Sterne,et al.  The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology , 2011, Epidemiology.

[4]  A. Mocroft,et al.  A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study , 2011, HIV clinical trials.

[5]  S. Deeks,et al.  HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.

[6]  S. Vollset.  Does the southern European cardiovascular mortality advantage extend to total mortality? 50-year trends in death risks between 40 and 70 years of age in Western European men and women , 2010, Scandinavian journal of public health.

[7]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[8]  Matthew Hickman,et al.  HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage , 2010, The Lancet.

[9]  A. Phillips,et al.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.

[10]  Rosanna Abbate,et al.  Adherence to Mediterranean diet and health status: meta-analysis , 2008, BMJ : British Medical Journal.

[11]  A. Mocroft,et al.  The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. , 2008, Central European journal of public health.

[12]  P. Morlat,et al.  Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic) , 2008, Journal of acquired immune deficiency syndromes.

[13]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[14]  JD Lundgren,et al.  Loss to follow‐up in an international, multicentre observational study , 2008, HIV medicine.

[15]  T. Rhodes,et al.  Access to syringes in three Russian cities: implications for syringe distribution and coverage. , 2008, The International journal on drug policy.

[16]  B. Yip,et al.  Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort , 2006, AIDS.

[17]  P. Morlat,et al.  Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.

[18]  Maria Prins,et al.  Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. , 2003, European journal of public health.

[19]  O. Kirk,et al.  Combination antiretroviral therapy and the risk of myocardial infarction. , 2003, The New England journal of medicine.

[20]  B. Yip,et al.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[21]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[22]  O. Kirk,et al.  Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study , 2003, AIDS.

[23]  F. Hamers,et al.  HIV in central and eastern Europe , 2003, The Lancet.

[24]  A. Mocroft,et al.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.

[25]  A. Mocroft,et al.  Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. , 1999, AIDS.

[26]  A. Mocroft,et al.  Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. , 1999, AIDS.

[27]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[28]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .